Daebongls.Co., Ltd. Overview
Daebong LS is a small-cap Korean specialty-materials company. It now calls itself a "cosmetics, pharmaceutical and bio materials platform". The core business is selling and making active and functional cosmetic ingredients. These are its own Jeju- and fermentation-derived actives plus a distribution portfolio from global majors BASF and Lubrizol (including Lipotec peptides). The company says it serves more than 800 OEM/ODM and brand customers.
A second leg is a GMP/PIC/S-certified active pharmaceutical ingredient (API) business focused on respiratory, hypertension and digestive therapies. This business is now moving into incrementally modified drugs (IMDs) and peptide APIs, including a liraglutide CDMO alliance with India's Shilpa Pharma Lifesciences.
The third leg is the 54–59%-owned P&K Skin Research Center, which runs human-application efficacy testing for cosmetics and gives the group a "material plus clinical data" offering. FY2025 revenue first passed KRW 100B. However, operating margins and free cash flow have weakened after the debt-funded move to the Songdo B&H Plex campus.
What the company does
Daebong LS sources, manufactures, formulates and sells raw materials. Its customers are cosmetics makers, pharmaceutical makers and (historically) food and feed producers. Third-party descriptions (Investing.com/S&P Global, MarketScreener) identify three operating divisions:
-
Cosmetic Ingredients.
-
Proprietary specialty actives, many based on Jeju Island botanicals: fresh green tea, black ginseng water, Jeju gulfweed, Artemisia capillaris, Jeju camellia oil, daengyuji citrus, basalt volcanic ash, ginseng flower.
-
Natural and synthetic functional ingredients for moisturising, protection, whitening, anti-ageing, hair care, anti-pollution, conditioning and colour.
-
Distributed commodity and specialty materials: aloe vera gel, beta-carotene, calamine, Diaformer, Emulgade, emulsifiers, emollients, polymers and thickeners.
-
-
Pharmaceutical Raw Materials.
-
Development and production of APIs for respiratory, hypertension, digestive and hyperlipidaemia therapies.
-
Named materials include almagate, bentonite, calcitriol, erdosteine and fish oil.
-
Excipient supply to Korean drug makers as an agent for global companies.
-
-
Food & Feed. Functional additives, proteins, amino acids, vitamins and fish feed. Compound fish feed is supplied to the affiliate Daebong LF Fishery Association, and the company owns a Bio-secure Aquaculture System (BAS) technology.
The consolidated group adds a clinical/efficacy-testing business through the listed subsidiary P&K Skin Research Center. P&K covers cosmetics, health functional foods, beauty devices and in-vitro testing.
Current revenue mix (H1 2026)
KIRS (8 Oct 2026) reports the H1 2026 sales mix as:
cosmetic materials 63%: - pharmaceutical materials 15%
other / subsidiaries 22%: (mainly P&K)
Under DART's reported segments, Butler shows the Q2 2026 mix as manufacturing 79%, research (P&K) 20% and rental 1%.
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Product vs service | Mainly product sales (ingredients and APIs, about 78–80% of revenue). Fee-for-service testing (P&K, about 20–22%). Small rental income after the Songdo campus completion (about 1%) |
| Own vs distributed | Mixed. The company manufactures its own actives and APIs at Incheon and acts as a distributor for BASF and Lubrizol (Lipotec) cosmetic materials and for global excipient makers. KIRS cites a portfolio of 1,200+ cosmetic materials. StockHub cites about 400 eco-natural and bio-synthetic derma materials, probably the proprietary or manufactured subset |
| Licensing | Emerging. The company targets technology transfers (out-licensing) of IMD candidates (L-erdosteine, epinaconazole co-crystal) by end-2026. No licensing revenue has been disclosed to date |
| Subscription | — |
| Customer types | Cosmetic OEM/ODM manufacturers, brand owners (including indie K-beauty brands), domestic pharmaceutical companies, overseas distributors/agents (20+ countries), and feed users |
| End-markets | Skincare and derma-cosmetics, hair care, post-procedure/aesthetic care, generic and IMD pharmaceuticals (respiratory, cardiovascular, GI), medical devices (Class II wound dressing), food/feed |
Value-chain position
Daebong LS sits upstream of K-beauty brand owners and contract manufacturers (Cosmax, Kolmar Korea and others) and of domestic pharmaceutical formulators. It combines three roles:
Ingredient innovator: own actives with Korean and international patents and publications.
Specialty distributor/formulation consultant: BASF/Lubrizol materials plus guide formulations.
Data provider: P&K efficacy claims substantiation.
The company's stated aim is a "one-stop" chain from material to formulation to clinical substantiation. The 2025 Songdo B&H Plex co-locates Daebong LS, the OEM/ODM affiliate UCL and P&K to deliver this (MT, 19 Dec 2025).
Company self-description vs independent view
Company self-description (2025–26 press releases): a "cosmetics, pharmaceutical and bio materials platform company". Its mission is to provide the best solutions so people can live healthier and more beautiful lives (SCC/UL Prospector company text, paraphrased). It emphasises a multi-brand, multi-category structure not dependent on any single brand or product line (CosinKorea, 18 Aug 2026).
Independent characterisation: a family-controlled small-cap. Its economic engine is cosmetic-ingredient trading and manufacturing with modest margins: FY2025 gross margin 27.9%, operating margin 7.2%. Historically the standalone parent earned very thin operating margins (1.5% in FY2020). Consolidated profitability has depended on the higher-margin P&K subsidiary and on non-operating financial income from a large portfolio of financial assets. The pharma IMD and peptide pipeline is option value, not yet a revenue line.
Strategy
Stated strategic themes (paraphrased from 2025–26 company communications)
-
"Cosmetics, pharmaceutical and bio materials platform." Integrate material development, formulation, manufacturing and clinical substantiation in one location (Songdo B&H Plex).
-
High-value bio materials. Shift the mix toward peptides, PDRN, exosomes, ceramides and DDS-encapsulated actives. In H2 2026 the company plans to raise the sales share of peptides and PDRN (CosinKorea, 18 Aug 2026).
-
"Medical beauty" as a new growth engine. Medical devices (DB JINO line) and derma products sold through hospitals, pharmacies and Olive Young; described as entering a sales-expansion phase in Q1 2026 (Financial News, 18 May 2026).
-
From API maker to IMD developer. Out-license L-erdosteine and the epinaconazole co-crystal (target end-2026). Commercialise vonoprazan and azilsartan IMDs and generic APIs. Peptide APIs (liraglutide via Shilpa). Management described the Nov 2025 conference as an "inflection point" (Finance Scope, 26 Nov 2025).
-
Globalisation of the ingredient business. Distributor agreements in about 20 countries (2024); partnership with Azelis Indonesia for ASEAN; trade shows in Korea, Asia, Japan and Europe.
-
Multi-brand, multi-category resilience. Avoid concentration on any single brand or product (CosinKorea, 18 Aug 2026).
-
Open innovation and national R&D. KEIT lutein project; participation in the Kookmin University-led KRW 22.2B advanced bio-materials programme; KHIDI global-GMP support.
Initiatives announced in the last 24 months
| Date | Initiative | Detail | Source |
|---|---|---|---|
| Sep 2024 – Nov 2025 | Shilpa GLP-1 alliance | NDA (Sep 2024) → MOU (Dec 2024) → production-schedule talks (Mar 2025) → Shilpa CTO presents a Korea and Thailand GLP-1 commercialisation roadmap at Daebong's conference (Nov 2025) | Dailypharm; Finance Scope |
| 2024–2025 | Songdo B&H Plex | Group HQ, R&D and clinical campus; construction contract about KRW 56.4B | Dealsite; MT |
| 2,025 | New cosmetic actives | L-PDRN First, RedCabbage ExoSkin, DecelAge Peptide, Tremella Dual-Oligo | CosinKorea |
| Jan 2026 | Medical device entry | DB JINO Algi Bio Cell MD (Class II) | Cosmorning |
| 2,026 | KHIDI global GMP support | Upgrade GMP and quality systems for pharmaceutical amino acids; build FDA regulatory capability for US/EU entry | Financial News, 7 Jul 2026 |
| Jul 2026 | KEIT lutein project | Lead organisation; KRW 5B total budget; Jun 2026–Dec 2030 (about 56 months); partners GS Caltex, Silicobio (KAIST-derived strain technology), Dankook University | Financial News; Geconomy, Jul 2026 |
| Jul 2026 | Kookmin University consortium | One of 17 organisations in a KRW 22.2B KEIT advanced bio-materials programme; Daebong responsible for microbial lutein | Financial News, 28 Jul 2026 |
| Jul 2026 | Business development | 6 NDAs at Interbiz 2026 (40+ BD meetings); 27 core follow-ups from CPHI Japan 2026 | MTN; CosinKorea |
ESG / sustainability commitments
These are qualitative:
-
upcycled ingredients (citron seed oil, carrot leaf);
-
COSMOS organic certification;
-
vegan fermentation;
-
precision fermentation to replace crop-based extraction (lutein vs marigold).
No quantified ESG targets were found.
Cost programmes and medium-term targets
Cost programmes: none disclosed.
Medium-term financial targets: none disclosed.
Management qualitative guidance: - FY2025: improved results expected from Hydro Skin Bond, ceramides/DDS, IMDs and peptides (Feb 2025).
- FY2026: another record expected (May 2026); H2 2026 profitability and growth expected to improve together as high-value bio materials scale (Financial News, 18 May 2026).
Third-party estimate: KIRS (8 Oct 2026) estimates FY2026 revenue of KRW 126.8B (+24.3%) and OP of KRW 13.2B (+80.1%, margin 10.4%). This is sponsored research with no rating or target price. The pharma pipeline is reflected conservatively.
Products & Services
Product-level revenue and pricing are not publicly disclosed. Launch years are given where press coverage dates them.
Cosmetic ingredients — proprietary actives ("Daebong ACTIVE")
| Product | Description / key claims | Target customer | Year surfaced | Source |
|---|---|---|---|---|
| Hydro Skin Bond | Bio-adhesive "skin bonding" material. Uses moisture from micro-wounds to knit skin rather than simply coating it; aimed at barrier repair. Bio-cellulose nano-fibre plus alginate-boronic acid chemistry | Derma brands, post-procedure care, medical device | 2,023 | Financial News, 15 Nov 2023; Cosmorning, 30 Aug 2024 |
| Adhesive hydrogel (all-in-one tissue adhesive) | Moisture-friendly adhesion that strengthens in wet conditions; optimal at skin pH 5.5–5.8. Two patent applications filed. About 10 Korean derma companies developing products with it (2024) | Derma, wound care | 2,024 | Asia Economy, 28 Aug 2024 |
| L-PDRN First | Vegan PDRN derived from lactic-acid bacteria | Aesthetic and post-procedure care | 2,025 | CosinKorea, 17 Nov 2025; 14 May 2026 |
| DecelAge Peptide | Peptide made by precision fermentation; positioned as a "longevity peptide" | Anti-ageing skincare | 2025–26 | CosinKorea, 14 May 2026 |
| RedCabbage ExoSkin | Exosome-type material derived from red cabbage | Aesthetic/derma | 2,025 | CosinKorea, 17 Nov 2025 |
| Tremella Dual-Oligo | In-house active; claims moisture signalling and pro-collagen effects beyond surface hydration | Skincare, slow-ageing | 2,026 | Medipharm Health, Jul 2026 |
| Tremellan-MC Extract | Concentrated Tremella fuciformis polysaccharide; 48-hour incubation; about 4x mannose vs standard extract. Moisturising, anti-ageing and antioxidant (in-vitro), with in-vivo safety | Skincare | c.2023 | SCC exhibitor sheet |
| Korean Citron (Yuja) Oil | Upcycled, solvent-free oil from citron seeds discarded in citron-tea production. In-vivo anti-wrinkle, moisture and brightening claims; allergen-controlled | Clean/upcycled beauty | c.2023 | SCC exhibitor sheet |
| Gojiberry Kombu™ | Postbiotic made with patented brewing technology based on Korean traditional methods; vegan fermentation | Microbiome skincare | c.2023 | SCC exhibitor sheet |
| Fermented kimchi-derived Bacillus extract | Vegan Bacillus fermented at low temperature for 3 days; about 3x quercetin; barrier and moisture | Microbiome skincare | 2,023 | Financial News, 15 Nov 2023 |
| Fermented Houttuynia and upcycled carrot-leaf extracts | Sebum control; "post-Houttuynia" positioning | Oil-control skincare | 2,023 | Financial News, 15 Nov 2023 |
| Plant mucin, plant collagen, fermented yuzu | Vegan alternatives credited with overseas agent growth in 2024 | Export brands | 2,024 | Financial News, 18 Feb 2025 |
| Protect Extract LS-2 | Anti-inflammatory; for seborrhoeic dermatitis and acne-prone skin | Acne/derma | — | UL Prospector |
| Jeju special ingredients | Fresh green tea, black ginseng water, Jeju gulfweed, Artemisia capillaris, Jeju camellia oil, daengyuji extract, basalt volcanic ash, Jeju Active Complex, ginseng-flower extract | Natural/clean beauty | Various | Investing.com/S&P profile |
| Skin-friendly ceramides and DDS-encapsulated barrier materials | Ceramide platform combined with drug-delivery (DDS) carriers for stability and penetration | Barrier repair | 2,025 | Financial News, 18 Feb 2025; CosinKorea, 17 Nov 2025 |
Cosmetic ingredients — distributed and partner portfolios
| Line | Description | Source |
|---|---|---|
| BASF materials | Base and functional materials used in "clean derma" guide formulations; BASF materials are shown at Daebong's trade booths | Financial News, 18 Feb 2025; MTN, 13 Jul 2026 |
| Lubrizol / Lipotec materials | Peptides and actives. Daebong credits synergy between its green-bio peptides and Lipotec products for 2024 growth. Joint "Lubrizol × Daebong LS" seminar held 29 May 2026 | Financial News, 18 Feb 2025; Medipharm Health 2026 |
| Functional commodities | Aloe vera gel, beta-carotene, calamine, Diaformer, Emulgade; conditioners, emulsifiers, emollients, polymers, thickeners, preservatives, colorants | MarketScreener |
Pharmaceutical raw materials and pipeline
| Product / candidate | Description | Status (Oct 2026) | Source |
|---|---|---|---|
| Respiratory APIs (incl. erdosteine) | Mucolytic/expectorant and cough APIs; flagship category | Commercial; growth credited in 2024; Japan exports after PMDA inspection (Mar 2024) | Financial News, 18 Feb 2025 |
| Hypertension APIs | Antihypertensive APIs for elderly patients | Commercial | Financial News, 18 Feb 2025 |
| Digestive and hyperlipidaemia APIs | Including almagate (antacid) | Commercial | Investing.com; MarketScreener |
| Other materials | Bentonite, calcitriol, fish oil; excipients as agent for global suppliers | Commercial | MarketScreener |
| Pharmaceutical amino acids | Focus of the 2026 KHIDI global-GMP regulatory support programme, aimed at FDA readiness | In upgrade | Financial News, 7 Jul 2026 |
| Liraglutide API (GLP-1 RA) | 32-amino-acid peptide made by a proprietary greener synthesis with shorter purification, higher purity and yield, and fewer impurities. Four patents. Scale-up at Shilpa's peptide GMP facility, with Daebong to hold domestic exclusive supply | Company targeted Korean launch in 2026; Shilpa reported R&D-stage process complete and API process validation planned for Apr–Sep 2025. Launch not confirmed in sources reviewed | MTN, 9 Sep 2024; Finance Scope, 17 Jul 2025 |
| L-erdosteine (IMD) | Single L-enantiomer, low-dose cough/expectorant; aims to lower dose burden and cost vs DL-erdosteine | Out-licensing targeted by end-2026; part of 6 NDAs signed at Interbiz 2026 | MTN, 10 Jul 2026 |
| Epinaconazole co-crystal (oral IMD) | Oral version of the topical onychomycosis drug (the Jublia ingredient); once-daily with lower liver burden. Patents to 2040; Japan patent completed earlier | Out-licensing targeted by end-2026; discussed with Japanese firms and CDMOs at CPHI Japan 2026 | Finance Scope, 26 Nov 2025; CosinKorea, 4 May 2026 |
| Vonoprazan fumarate new crystal form | Patent-based IMD (P-CAB acid blocker) | Commercialisation being pursued | MTN, 10 Jul 2026 |
| Azilsartan new salt and combination | Patent-based IMD (ARB antihypertensive) | Commercialisation being pursued | MTN, 10 Jul 2026 |
Medical devices and derma products
| Product | Description | Status | Source |
|---|---|---|---|
| DB JINO Algi Bio Cell MD | Class II adhesive transparent wound dressing with 0.3% Hydro Skin Bond. Bio-responsive pH adhesion, (+)BCNF collagen-like scaffold. For post-laser/MTS, post-surgical and barrier-damage care; promotes granulation tissue and ECM synthesis. Described as Korea's first bio-cellulose composite hydrogel adhesive dressing | Domestic launch planned Aug 2025 (per July 2025 report); first-MD announcement Jan 2026. Distribution enquiries from Sri Lanka, China, Japan, Bangladesh and Thailand; NDAs and pricing talks underway | Cosmorning, 22 Jul 2025 & 22 Jan 2026; CosinKorea, 4 May 2026 |
| DB JINO Multi ATO Cream | Derma cream for atopic-type skin, part of the DB JINO line | Presented at Interbiz 2026 | MTN, 10 Jul 2026 |
Food, feed and aquaculture
| Product | Description | Source |
|---|---|---|
| Food additives | Functional additives, proteins, amino acids, vitamins | Investing.com |
| Compound fish feed | Supplied to the affiliate Daebong LF Fishery Association; eel farming used to demonstrate compound-feed results versus raw feed (Korea's raw-feed share is above 70%) | Financial News, 18 Apr 2022 |
| BAS (Bio-secure Aquaculture System) | Pathogen-free aquaculture system (2016 invention; patents in KR, JP, CN, EU); revenue from installation plus maintenance; 3 sites built by 2022 | Financial News, 18 Apr 2022 |
| Precision-fermentation lutein (development) | Microbial lutein to replace marigold extraction, for cosmetics (blue-light/photo-ageing), health foods and feed | Financial News, 7 Jul 2026 |
Clinical and testing services (P&K Skin Research Center)
| Service | Description | Source |
|---|---|---|
| Cosmetic human-application tests | Efficacy and safety claims testing. KIRS calls P&K Korea's No. 1 skin human-application testing company. 98 in-house protocols and 473 claim phrasings developed (2024) | MT, 18 Feb 2025; KIRS, Mar 2026 |
| Health functional food tests | Orders up more than 10x YoY in 2024 | MT, 18 Feb 2025 |
| Beauty-device and in-vitro testing | Extension areas | KIRS, Mar 2026 |
| Global regulatory consulting | Supports K-beauty overseas expansion | CosinKorea, 17 Nov 2025 |
| K-Onirika Cosmetics (85.09%-owned by P&K, founded 2023) | Colour-cosmetics research and contract development; projects with North American and European brands | KIRS, Mar 2026; CosinKorea, 17 Nov 2025 |
Financial Narrative
Sources: Butler / ETFShopping (DART-aggregated annual consolidated revenue, operating income and net income, FY2016–FY2025); Valueline (FY2025 income-statement detail, balance sheets FY2022–FY2025 and Jun-2026, cash-flow and ratio data on a trailing-twelve-month basis); MarketScreener (FY2022–FY2023 controlling net income and EPS). Units: KRW B unless stated. FY2021 balance-sheet and FY2021–FY2024 cash-flow detail were not available in the sources reviewed.
Income statement
Notes on the table:
EBITDA: The KRW 11.8B figure is computed as OP 7.33 plus depreciation 4.41 plus amortisation 0.06. Valueline's own EBITDA field shows KRW 17.6B, which appears to include non-operating items, so it is not used here.
Margins and growth
Revenue CAGR FY2021–FY2025: 5.3% (83.0 → 102.1, computed). Over ten years (FY2016 KRW 71.0B → FY2025 KRW 102.1B) the CAGR is about 4.1%. Revenue was flat for several years, from KRW 71.0B in FY2016 to 69.5B in FY2019, before the post-2020 step-up.
Longer history (context)
Source: ETFShopping; SK Securities (Jul 2020).
Commentary — income statement.
-
A margin-compression story. Consolidated operating margin fell from 15.8% (FY2016) to 7.2% (FY2025) while revenue rose about 44%. The mix moved toward lower-margin distributed cosmetic materials. The once ~50%-margin P&K became a smaller share of profit after its FY2023 downturn.
-
FY2023 trough. Revenue fell 6.3% and OP fell 54% to KRW 3.8B. The drivers were P&K's revenue drop (−17.3%, OP down from KRW 5.6B to 1.4B) and a weak domestic cosmetics market.
-
FY2024 recovery. OP more than doubled to KRW 9.1B. Management credited synergies between its peptides and Lipotec products, BASF-based clean-derma formulations, strong respiratory and hypertension APIs, and Japan exports after the March 2024 PMDA inspection (Financial News, 18 Feb 2025).
-
FY2025: record revenue, lower OP. Revenue reached KRW 102.1B (+8.6%) but OP fell 19% to KRW 7.3B. The company points to higher SG&A from the Songdo move and headcount additions, which it describes as structural investment (CosinKorea, 17 Nov 2025). Implied Q4 2025 OP was only about KRW 0.6B (FY KRW 7.3B minus 9M KRW 6.7B), on implied Q4 revenue of about KRW 24.9B.
-
Net income above OP. FY2025 net income (KRW 11.9B) exceeded OP (KRW 7.3B). Finance income of KRW 13.7B included derivative gains of KRW 6.6B, fair-value gains on financial assets of KRW 2.9B and interest income of KRW 3.4B (Valueline TTM Dec-2025). Earnings quality is therefore heavily dependent on the investment portfolio and FX hedges.
-
2026 inflection risk. H1 2026 revenue rose 19.7% to KRW 62.7B, but OP fell 5.1% to KRW 5.7B and net income fell 79% to KRW 2.4B. Drivers (Dailypharm, 29 Sep 2026):
-
finance income fell from KRW 8.9B to 3.5B;
-
finance costs rose from KRW 1.6B to 6.3B, including a KRW 3.8B currency-futures loss;
-
interest expense rose about 14x to KRW 1.89B. Q2 2026 alone: revenue KRW 33.7B, OP KRW 3.7B, NI KRW 1.8B (ETFShopping). Q1 2026 basic EPS was KRW −1.16 (Investing.com).
-
Balance sheet
Latest interim (30 Jun 2026, Valueline):
-
total assets KRW 277.4B; cash KRW 10.5B; ST financial assets KRW 7.2B; other current assets KRW 48.4B;
-
short-term borrowings KRW 12.7B; long-term borrowings KRW 39.4B; CB KRW 28.4B; total debt about KRW 80.4B;
-
total liabilities KRW 101.3B; total equity KRW 176.2B; BPS KRW 12,787;
-
equity-method and related investments rose to KRW 16.5B from KRW 4.0B.
Commentary — balance sheet.
Asset-light to asset-heavy: Total assets grew 42% over FY2022–FY2025, funded by debt. PP&E plus investment property rose from KRW 38.4B to KRW 108.1B as the Songdo B&H Plex was built (construction contract about KRW 56.4B).
Leverage built quickly: Narrow net debt rose from KRW 12.3B (FY2022) to KRW 56.9B (FY2025) and about KRW 62.7B (Jun 2026). The KRW 30B CB (Sep 2024) and KRW 39.4B of long-term bank borrowing were the main sources.
Large financial-asset buffer: "Other current assets" of KRW 48–79B appear to be largely financial investments. Dailypharm reported fund investments of about KRW 60B in 2021 ("펀드 투자 600억"). The composition is not itemised in the sources. Including these assets, the group remains net cash on a broad basis (for example, FY2025 broad net cash of about KRW −1.8B net debt, i.e. roughly balanced).
Large minority interest: About 19% of equity belongs to minority holders, mostly the ~41–45% of P&K not owned by the group.
Low intangibles, no goodwill: No large acquisitions have been made.
Heavy working capital: Inventories rose from KRW 13.7B (FY2023) to KRW 20.3B (Jun 2026) as the distribution catalogue and export pipeline widened.
Cash flow
Source: Valueline cash-flow statement, trailing-twelve-month column at Dec-2025 (equal to FY2025).
Trailing views:
-
TTM to Jun 2026: OCF KRW 7.6B; capex KRW 9.3B; FCF about KRW −1.7B; new equity-method investment KRW 11.9B; dividends paid KRW 1.1B.
-
H1 2026 OCF fell 26.2% YoY to KRW 3.6B (Dailypharm, 29 Sep 2026).
-
FY2024 cash flows were not itemised in the sources reviewed. Construction in progress rose from KRW 9.0B to 46.4B during FY2024, which implies heavy FY2024 capex.
Commentary — cash flow. OCF of KRW 8.9B in FY2025 was well below net income of KRW 11.9B, reflecting non-cash finance gains and working-capital build. Campus capex drove deeply negative FCF of about KRW −30.6B in FY2025. Capex fell sharply in H1 2026 once the campus was finished. Free cash flow should normalise from FY2026, but there is little room for further large investment without more debt. No buybacks were made. Dividends are small (KRW 50/share; about KRW 1.0B a year).
Ratio analysis
Notes on the ratios:
-
FY2025 ROE, ROA, ROIC and interest coverage are Valueline figures.
-
FY2023 ROE, ROA for FY2023–FY2024, and the balance-sheet ratios are computed from the tables above. ROA uses consolidated net income over average assets, except FY2025, which uses Valueline's figure.
-
Working-capital days use FY2025 year-end balances against FY2025 revenue and cost of sales.
Latest trailing ratios (TTM to Jun 2026, Valueline): ROE 0.96%; ROA 0.49%; ROIC 6.83%; operating margin 6.25%; net margin 1.21%; interest coverage 2.0x; current ratio 3.64x; liabilities to owners' equity 71.4%.
Commentary — ratios.
-
Returns are low and falling: FY2025 ROE of 7.1% fell to about 1% on a trailing basis.
-
Interest coverage dropped from 14.3x (TTM Sep 2025) to 2.0x (TTM Jun 2026) as new borrowing costs arrived and operating income lagged.
-
Liquidity is ample (current ratio above 3.5x) because of the financial-asset portfolio.
-
The cash conversion cycle of about 135 days is long for a materials distributor. It reflects broad inventory carried for 800+ customers and long domestic receivable terms.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Key products / services |
|---|---|---|
Manufacturing (제조) | The parent company's manufacturing and trading: cosmetic ingredients (own and distributed), APIs and excipients, food/feed materials. Revenue tracks the parent's standalone revenue | Jeju actives, peptides, PDRN, exosome, Hydro Skin Bond, BASF/Lubrizol distribution; erdosteine and other respiratory/hypertension/GI APIs; feed |
Research (연구) | P&K Skin Research Center and its subsidiary K-Onirika Cosmetics | Human-application efficacy and safety testing (cosmetics, health functional foods, devices), in-vitro testing, regulatory consulting; colour-cosmetics R&D (K-Onirika) |
Wholesale (도매) | Small trading activity | Not detailed |
Rental (임대) | New from 2025: lease income from the part of Songdo B&H Plex leased to affiliates (reclassified as investment property) | Office/R&D space leased to UCL and P&K |
Revenue by Segment
| Segment (KRW Bn) | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
Manufacturing (FY2025 = parent standalone revenue proxy) | 61.2 | 65.1 | 75.2 | 72.5 | 75.8 | 79.1 |
Research / clinical testing (FY2025 = P&K consolidated revenue) | 14.7 | 17.5 | 17.9 | 14.8 | 17.8 | 22.8 |
Wholesale | 0.36 | 0.34 | 0.33 | 0.29 | 0.30 | — |
Unallocated adjustments | — | — | — | -0.02 | -0.01 | — |
Total consolidated revenue | 76.3 | 83.0 | 93.5 | 87.6 | 94.0 | 102.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
Research segment / P&K operating income (KRW Bn) | 7.2 | 6.5 | 5.6 | 1.4 | 2.6 | 3.9 |
P&K operating margin (%) | 49.0 | 37.1 | 31.3 | 9.5 | 14.6 | 17.1 |
Parent standalone operating income (KRW Bn) | 0.9 | — | — | — | — | — |
Parent standalone net income (KRW Bn) | — | — | — | 1.7 | 4.2 | 7.5 |
Parent standalone equity (KRW Bn) | — | — | — | 79.2 | 87.2 | 94.1 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Manufacturing share of revenue (%) | 78.4 | 80.4 | 82.8 | 80.6 | 77.5 |
Research share of revenue (%) | 21.1 | 19.1 | 16.9 | 18.9 | 22.3 |
Manufacturing YoY growth (%) | 6.4 | 15.5 | -3.6 | 4.6 | 4.4 |
Research YoY growth (%) | 19.0 | 2.3 | -17.3 | 20.3 | 28.1 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 83.0 | 93.5 | 87.6 | 94.0 | 102.1 |
Revenue growth YoY (%) | 8.8 | 12.7 | -6.3 | 7.2 | 8.6 |
Cost of sales (KRW Bn) | — | — | — | — | 73.6 |
Gross profit (KRW Bn) | — | — | — | — | 28.5 |
SG&A incl. R&D (KRW Bn) | — | — | — | — | 21.2 |
Operating income (KRW Bn) | 9.7 | 8.2 | 3.8 | 9.1 | 7.3 |
D&A (KRW Bn) | — | — | — | — | 4.5 |
EBITDA = OP + D&A (KRW Bn, computed) | — | — | — | — | 11.8 |
Finance income (KRW Bn) | — | — | — | — | 13.7 |
Finance costs (KRW Bn) | — | — | — | — | 7.1 |
Pre-tax income (KRW Bn) | — | — | — | — | 14.7 |
Income tax (KRW Bn) | — | — | — | — | 2.8 |
Net income, consolidated (KRW Bn) | 10.0 | 11.8 | 6.2 | 9.7 | 11.9 |
Net income to owners of parent (KRW Bn) | — | 8.6 | 4.2 | — | 10.1 |
Non-controlling interest (KRW Bn) | — | — | — | — | 1.9 |
Basic EPS (KRW) | — | 788 | 382 | — | 907 |
Diluted EPS (KRW) | — | 788 | 382 | — | — |
Dividend per share (KRW) | — | — | — | — | 50 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | — | — | — | — | 27.9 |
Operating margin (%) | 11.7 | 8.8 | 4.3 | 9.7 | 7.2 |
EBITDA margin (%, computed) | — | — | — | — | 11.6 |
Net margin, consolidated (%) | 12.0 | 12.6 | 7.1 | 10.3 | 11.7 |
R&D / revenue (%) | — | — | — | — | 5.5 |
Income Statement and Margin Analysis (%) (FY2016–FY2020)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 71.0 | 65.7 | 71.8 | 69.5 | 76.3 |
Operating income (KRW Bn) | 11.2 | 9.1 | 7.9 | 7.4 | 8.1 |
Operating margin (%) | 15.8 | 13.9 | 11.0 | 10.6 | 10.6 |
Balance Sheet and Per-Share Data
| Metric (KRW Bn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets | 186.1 | 194.9 | 238.7 | 265.0 |
Current assets | 130.2 | 113.2 | 115.2 | 111.0 |
Cash and equivalents | 7.2 | 14.2 | 18.1 | 7.6 |
Short-term financial assets | 5.4 | 3.1 | 5.2 | 7.1 |
Other current assets (largely financial investments) | 78.8 | 59.6 | 54.0 | 55.1 |
Trade receivables | 23.2 | 20.7 | 19.1 | 21.5 |
Inventories | 14.7 | 13.7 | 16.4 | 18.5 |
Property, plant and equipment | 38.4 | 44.8 | 80.5 | 59.9 |
of which construction in progress | 2.0 | 9.0 | 46.4 | 0.1 |
Investment property | 0.0 | 0.0 | 0.0 | 48.2 |
Goodwill | 0.0 | 0.0 | 0.0 | 0.0 |
Other intangibles | 0.5 | 0.7 | 0.8 | 0.9 |
Investments (equity-method and other) | 15.9 | 35.1 | 41.1 | 41.5 |
Current liabilities | 34.8 | 40.9 | 40.0 | 20.4 |
Short-term borrowings | 21.4 | 27.9 | 15.7 | 4.3 |
Current portion of long-term debt | 2.2 | 2.1 | 0.6 | 0.7 |
Convertible bonds (carrying value) | 0.0 | 0.0 | 25.1 | 27.2 |
Long-term borrowings | 1.3 | 0.1 | 8.0 | 39.4 |
Total debt (computed, excl. leases) | 24.8 | 30.2 | 49.4 | 71.6 |
Net debt, narrow (debt − cash − ST financial assets) | 12.3 | 12.9 | 26.1 | 56.9 |
Total liabilities | 37.7 | 41.7 | 74.7 | 90.0 |
Equity attributable to owners | 117.2 | 120.7 | 131.8 | 141.2 |
Non-controlling interests | 31.3 | 32.5 | 32.2 | 33.7 |
Total equity | 148.4 | 153.2 | 164.0 | 174.9 |
Working capital (CA − CL) | 95.4 | 72.3 | 75.2 | 90.6 |
Book value per share (KRW) | 10,567 | 10,889 | 11,885 | 12,737 |
Cash Flow
| Metric (KRW Bn) | FY2025 |
|---|---|
Operating cash flow | 8.9 |
Capital expenditure (PP&E) | 39.5 |
Intangible asset purchases | 0.2 |
Free cash flow (OCF − capex, computed) | -30.6 |
Investing cash flow | -37.6 |
Financing cash flow | 18.3 |
Dividends paid | 1.0 |
Share buybacks | 0.0 |
Depreciation and amortisation | 4.5 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE, controlling basis (%) | — | 3.5 | — | 7.1 |
ROA (%) | — | 3.3 | 4.5 | 3.8 |
ROIC (%) | — | — | — | 6.2 |
Current ratio (x) | 3.74 | 2.77 | 2.88 | 5.44 |
Total debt / total equity (%) | 16.7 | 19.7 | 30.1 | 40.9 |
Total liabilities / owners' equity (%) | 32.2 | 34.5 | 56.7 | 63.8 |
Net debt (narrow) / EBITDA (x) | — | — | — | 4.8 |
Interest coverage, OP / interest (x) | — | — | — | 4.0 |
Asset turnover (x) | — | 0.46 | 0.43 | 0.41 |
Days sales outstanding (days, computed) | — | — | — | 77 |
Days inventory outstanding (days, computed) | — | — | — | 92 |
Days payables outstanding (days, computed) | — | — | — | 34 |
Cash conversion cycle (days, computed) | — | — | — | 135 |
Revenue by Region and Revenue by Region (%)
| Region (KRW Bn) | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
South Korea (domestic) | 74.7 | 81.2 | 92.2 | 86.0 | 92.4 | 100.1 |
Export (direct) | 1.58 | 1.75 | 1.34 | 1.59 | 1.58 | 1.92 |
Export share of revenue (%) | 2.1 | 2.1 | 1.4 | 1.8 | 1.7 | 1.9 |
Growth (%)
| Growth (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Domestic YoY | 8.7 | 13.5 | -6.7 | 7.4 | 8.3 |
Direct export YoY | 10.8 | -23.4 | 18.4 | -0.5 | 21.5 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 7,990 | 9,160 | 13,440 | 11,650 |
Year-end market cap (KRW Bn) | 88.6 | 101.6 | 149.0 | 129.2 |
Year-end P/B (x) | 0.76 | 0.84 | 1.13 | 0.91 |
Performance Details
| Performance | Return |
|---|---|
YTD 2026 (vs 30 Dec 2025 close of KRW 11,650) | -37.0% |
About 1 year | About -41% to -46% (Investing.com one-year change, Jul–Aug 2026) |
Since end-FY2023 (about 2.8 years) | -19.9% |
Since end-FY2022 (about 3.8 years) | -8.1% |
5-year | Not computed (FY2021 price not available in sources) |
Valuation Multiples
| Multiple | Daebong LS | Sunjin Beauty Science | P&K (subsidiary) | Hyundai Bioland | Samyang KCI |
|---|---|---|---|---|---|
P/E, trailing (x) | 58.3–61.2 (TTM, depressed earnings) | 17.3 | 14.7 | — | — |
P/E, forward (x) | 6.2 (KIRS FY2026E basis); fPER 24.6 (Butler) | 10.9 (Butler fPER) | — | — | — |
EV/EBITDA (x) | 11.5 (TTM Jun 2026; Valueline definition) | — | — | — | — |
EV/Sales (x) | About 1.4 (computed: market cap 81.4 + narrow net debt 62.7 + NCI 34.4 ≈ 178.5 / TTM revenue 112.4 ≈ 1.59 incl. NCI; about 1.3 excl. NCI) | — | — | — | — |
P/B (x) | 0.56–0.57 | 1.00 | 0.67 | — | — |
P/S (x) | 0.74 (TTM) | — | — | — | — |
Analyst Ratings & Targets
| Date | Coverage | Rating / target | Key points |
|---|---|---|---|
8 Oct 2026 | KIRS (Korea IR Council, sponsored) | — | FY2026E revenue KRW 126.8B, OP KRW 13.2B; re-rating possible if cosmetics growth, co-developed materials, P&K margins and API commercialisation are confirmed |
28 Sep 2026 | Hana Securities | — | Report on H1 K-beauty-driven growth |
Jan 2023 | KIRS | — | "Three burrows" thesis (cosmetics, APIs, fish feed); valuation near historical lows |
Jul 2020 | SK Securities | Not Rated | Beneficiary of functional cosmetics and quality-certification demand; P&K IPO |
Capital Markets
| Item | Detail | Source |
|---|---|---|
Dividend per share, FY2025 | KRW 50 (annual) | ETFShopping; Valueline |
Dividend yield | About 0.43% (Valueline, on year-end basis) to about 0.66% (current price) | Valueline; ETFShopping |
Payout ratio, FY2025 | About 5% | ETFShopping |
Dividends paid, FY2025 | About KRW 1.0B | Valueline |
Dividend policy | No formal policy disclosed | — |
Buybacks | Treasury shares of about KRW 1.34B, held since FY2023 (about 1.25% of shares). No current buyback authorisation identified. No cancellations | Valueline; Butler |
Capital Markets — Moody's / S&P / Fitch
| Item | Detail |
|---|---|
Moody's / S&P / Fitch | Not rated |
Domestic ratings | None identified |
Short-term borrowings | KRW 12.7B (30 Jun 2026), up from KRW 4.3B at end-FY2025 |
Long-term borrowings | KRW 39.4B (30 Jun 2026) |
Analyst Conclusions
Management guidance
-
No numerical guidance.
-
Management expects a second consecutive record year in FY2026 (May 2026).
-
In H2 2026 it targets a higher mix of peptide and PDRN bio materials and concrete commercialisation of IMDs and generic APIs, aiming for both revenue growth and better margins (CosinKorea, 18 Aug 2026).
Third-party expectations
KIRS FY2026E: revenue KRW 126.8B (+24.3%), OP KRW 13.2B (+80.1%), OP margin 10.4%. This implies H2 2026 revenue of about KRW 64B and OP of about KRW 7.5B, versus H1 OP of KRW 5.7B. No sell-side consensus exists.
Bull case
-
Operating leverage on a scaled base. Revenue has grown for two years and hit quarterly records (Q1 2026 KRW 29.1B; Q2 KRW 33.7B). Campus capex is largely done (H1 2026 capex well below FY2025's KRW 39.5B). Margins could revert toward the 10–12% achieved as recently as H1 2025 (11.4%), as KIRS models.
-
Free pipeline optionality. At about 0.57x book, the market assigns little value to two IMDs targeted for out-licensing by end-2026, the liraglutide API with Shilpa and the DB JINO device line. A single licensing deal or a confirmed liraglutide supply contract would be a material re-rating trigger for a KRW 81B company.
-
K-beauty structural growth plus P&K recovery. Korean cosmetics exports rose 27% in H1 2026. P&K's FY2025 revenue grew 27.7% with OP up 50%, and its backlog grew 20% in Q1 2026. Company-reported overseas cosmetic-material sales surged (North America +128% in H1 2026).
Bear case
-
Earnings quality and leverage. Reported profits have relied on finance income (FY2025 KRW 13.7B vs OP KRW 7.3B). In H1 2026 that reversed: NI fell 79%, with an FX-futures loss and 14x higher interest expense. Narrow net debt is about KRW 63B and coverage is 2.0x. The headline P/E of about 60x shows how thin core earnings are.
-
Structurally low-margin core. Operating margin has fallen for a decade, from 15.8% to 7.2%. The standalone parent historically earned 1–5% margins. Direct exports are only about 2% of revenue, and distribution dependence limits pricing power.
-
Pipeline slippage and governance discount. Liraglutide has been guided to "next year" since 2024 with no confirmed contract. IMD deals remain at NDA stage. Related-party leasing, subsidiary loans to an impaired entity and family control may keep the stock at a persistent discount despite asset backing.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Nov 2026 | Q3 2026 report: watch operating margin recovery (above 9%), FX/derivative results and interest expense |
| By Dec 2026 | Signing (or not) of L-erdosteine or epinaconazole co-crystal technology-transfer agreements |
| 2026–27 | Liraglutide: Shilpa process validation → Korean import API registration → exclusive supply contract |
| Feb–Mar 2027 | FY2026 results vs KIRS (KRW 126.8B / 13.2B); dividend decision; AGM agenda |
| Ongoing | Net-debt trajectory (short-term borrowings KRW 12.7B), CB terms and any refinancing; new equity-method investment (KRW 11.9B in H1 2026) — identity and rationale |
| Ongoing | DB JINO MD distribution contracts in Asia; Azelis ASEAN traction |
| Ongoing | P&K margins and the subsidiary K-Onirika's capital position |
| Ongoing | K-beauty export data (MFDS monthly), US IOR regulation, KRW/USD rate |
Analyst verdict
Daebong LS is a value stock with a profitability problem. On the surface it looks deeply cheap: it trades at about 0.57x book (BPS KRW 12,787 versus a price of about KRW 7,340), has a long operating record, holds a sizeable financial-asset portfolio and owns a majority stake in Korea's leading skin-efficacy testing house.
Two years of record revenue confirm the company is a real beneficiary of the K-beauty export cycle. Its breadth (1,200+ materials, 800+ customers, BASF and Lubrizol partnerships) gives it a defensible distribution moat in the Korean market.
The investment case, however, cannot rest on the top line. Core operating profitability has eroded for a decade, and FY2025's KRW 11.9B net income flattered a KRW 7.3B operating result. The KRW 13.7B of finance income behind that gap reversed sharply in H1 2026. Meanwhile the Songdo campus turned a net-cash balance sheet into one with about KRW 63B of narrow net debt and only 2x interest coverage. Some of that campus is leased to affiliates at an initial loss.
Until operating margins show a durable recovery toward double digits and free cash flow turns positive, the low P/B multiple is partly earned rather than purely an anomaly. KIRS's FY2026 OP estimate of KRW 13.2B implies a sharp H2 rebound.
The real upside lies in pipeline monetisation. A single IMD out-licensing deal (targeted by end-2026), a confirmed liraglutide supply contract or meaningful medical-device distribution would add high-margin revenue the market currently ignores. These events are binary, and timelines have already slipped.
Overall assessment: speculative-value, event-driven. The balance-sheet asset cover limits downside. The re-rating case depends on evidence over the next two to three quarters: margin recovery, deleveraging and at least one signed licensing deal. Investors should demand that evidence before underwriting the pipeline, and should monitor related-party dealings and the FX hedging policy closely.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure / background | Age | Source |
|---|---|---|---|---|
Park Jin-oh (박진오) | CEO (대표이사); co-CEO of P&K Skin Research Center (since Mar 2021) | Second-generation owner; largest shareholder since Sep 2019; physician by training with expertise in API and cosmetic-material R&D and skin science; publicly fronting the company since at least 2009 | About 55 (reported as 50 in Apr 2021) | Dailypharm, 27 Apr 2021; KIRS P&K report, Mar 2026; eToday, 2009 |
Park Jong-ho (박종호) | Listed alongside Park Jin-oh as company representative in corporate registries (NICE D&B / ETFShopping) | — | — | Incruit; ETFShopping |
Son Chang-woo | Director; Head of Finance Management Department | — | 54 | Investing.com profile |
Kim Yong-kil | Director; Chief of Research & Development | — | 61 | Investing.com profile |
Jung Cheol-seug | Independent outside director | — | 52 | Investing.com profile |
Lee Hae-kwang (이해광) | Co-CEO of subsidiary P&K | — | — | CosinKorea, 17 Nov 2025 |
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Park Jin-oh and 8 related parties | 50.93% | 30 Sep 2022 | KIRS, Jan 2023 |
of which Park Jin-oh | 22.6% | 30 Sep 2022 | KIRS, Jan 2023 |
Minority shareholders (10,899 holders) | 40.9% | 31 Dec 2025 | ETFShopping (FY2025 annual report) |
Treasury shares | about 1.25% | 2026 | Butler |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning vs Daebong LS |
|---|---|---|---|
Cosmetic ingredients (Korea) | Hyundai Bioland (KOSDAQ: 052260; Hyundai Department Store Group) | Natural cosmetic and health-food materials, brand distribution (Nestlé Health Science), medical devices | Larger and more profitable; brokers describe it as No. 1 in Korean natural cosmetic materials (Shinhan, via SmartToday) |
Cosmetic ingredients (Korea) | Sunjin Beauty Science (KOSDAQ: 086710) | Cosmetic materials (UV filters, microbeads, surfactants), ODM/OEM, clinical centre (SCRC) | Similar size; also integrating materials, ODM and clinical; FDA-registered materials plant |
Cosmetic and personal-care materials (Korea) | Samyang KCI (KOSDAQ: 036670; Samyang Group) | Cationic polymers, surfactants, polyglycerins, delivery systems | Larger; EcoVadis Platinum; more commodity/functional |
Cosmetic actives (Korea) | BioFD&C | Plant-cell and bio actives, exosomes | Direct competitor in bio actives; also in the Kookmin consortium |
Global cosmetic actives | Givaudan Active Beauty, Croda (Sederma), Symrise, DSM-Firmenich, Ashland | Global specialty-actives majors | Far larger; set the price and innovation benchmarks; Daebong competes on K-beauty speed and local service |
Global (partners and competitors) | BASF, Lubrizol (Lipotec) | Global suppliers distributed by Daebong | Partners. Distribution dependence is a risk if principals go direct or switch distributors |
APIs (Korea) | Domestic API makers (e.g., Kyongbo Pharm, Kukjeon Pharm, Hwail Pharm) | Generic API producers | Industry under margin pressure from drug-price reform and a high KRW/USD rate (Dailypharm headline, Sep 2026). Company-specific comparisons not compiled |
Peptide APIs / GLP-1 | Global peptide CDMOs and generic liraglutide API makers | — | Daebong is a new entrant through the Shilpa partnership |
Clinical efficacy testing (P&K) | Global Medical Research Center, Dermapro, Sunjin's SCRC, others | Korean skin-testing CROs | KIRS/company describe P&K as the domestic No. 1 |
Peer Comparison FY2025
| Metric | Daebong LS (078140) | Hyundai Bioland (052260) | Sunjin Beauty Science (086710) | Samyang KCI (036670) |
|---|---|---|---|---|
Latest annual revenue (KRW Bn) | 102.1 (FY2025) | 119.5 (FY2024 consolidated); about 130.5 (FY2025 standalone) | 80.8 (FY2025) | about 119.0 (FY2024E, KIRS estimate) |
Revenue growth (%) | 8.6 (FY2025) | 17.5 (FY2024); 9M-2025 Q1–Q3 revenue growth 5–17% per quarter | 1.8 (FY2025) | 5.2 (FY2024E) |
Operating income (KRW Bn) | 7.3 (FY2025) | 16.4 (FY2024); 15.2 (9M-2025) | 6.1 (FY2025) | about 17.7 (FY2024E) |
Operating margin (%) | 7.2 | 13.7 (FY2024); about 14.6 (9M-2025, computed) | 7.5 | about 14.9 (FY2024E) |
R&D intensity (%) | 5.5 | — | — | — |
Valuation (latest available) | TTM PER about 58–60x; PBR 0.56–0.57x | — | PER 17.3x; PBR 1.00x; dividend yield 2.83% | — |



